ES2725328T3 - Método para la administración de antígenos - Google Patents
Método para la administración de antígenos Download PDFInfo
- Publication number
- ES2725328T3 ES2725328T3 ES13726297T ES13726297T ES2725328T3 ES 2725328 T3 ES2725328 T3 ES 2725328T3 ES 13726297 T ES13726297 T ES 13726297T ES 13726297 T ES13726297 T ES 13726297T ES 2725328 T3 ES2725328 T3 ES 2725328T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- asc
- carrier
- antigen
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201204773 | 2012-04-24 | ||
| PCT/IB2013/053079 WO2013160807A1 (en) | 2012-04-24 | 2013-04-18 | A method for antigen delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2725328T3 true ES2725328T3 (es) | 2019-09-23 |
Family
ID=48539332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13726297T Active ES2725328T3 (es) | 2012-04-24 | 2013-04-18 | Método para la administración de antígenos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9725491B2 (pl) |
| EP (1) | EP2841110B1 (pl) |
| JP (1) | JP6026645B2 (pl) |
| CN (1) | CN104684586B (pl) |
| ES (1) | ES2725328T3 (pl) |
| HU (1) | HUE043215T2 (pl) |
| PL (1) | PL2841110T3 (pl) |
| PT (1) | PT2841110T (pl) |
| WO (1) | WO2013160807A1 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220100664A (ko) * | 2019-11-14 | 2022-07-15 | 보가지치 유니버시테시 | 암 면역요법에서의 asc speck |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6756196B2 (en) | 1999-06-28 | 2004-06-29 | Millennium Pharmaceuticals, Inc. | Molecules of the card-related protein family and uses thereof |
| US6911306B1 (en) | 1999-10-18 | 2005-06-28 | Emory University | TMS1 compositions and methods of use |
| JP2007522118A (ja) * | 2004-01-30 | 2007-08-09 | ペプリン バイオリピッズ ピーティーワイ エルティーディー | 治療用分子および担体分子 |
| ATE426168T1 (de) * | 2004-12-23 | 2009-04-15 | Hoffmann La Roche | Verwendung von asc als marker fur kolorektalkarzinome |
| CA2585788C (en) * | 2004-12-23 | 2013-03-05 | F. Hoffmann-La Roche Ag | Use of cyfra 21-1 as a marker for colorectal cancer |
| WO2009014863A2 (en) | 2007-06-29 | 2009-01-29 | Thomas Jefferson University | Asc and pyrin-asc pyroptosomes and uses thereof |
| US8685400B2 (en) | 2007-07-30 | 2014-04-01 | University Of Miami | Modulating inflammasome activity and inflammation in the central nervous system |
| US8334101B2 (en) * | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
-
2013
- 2013-04-18 CN CN201380033558.3A patent/CN104684586B/zh active Active
- 2013-04-18 WO PCT/IB2013/053079 patent/WO2013160807A1/en not_active Ceased
- 2013-04-18 PL PL13726297T patent/PL2841110T3/pl unknown
- 2013-04-18 US US14/396,632 patent/US9725491B2/en active Active
- 2013-04-18 ES ES13726297T patent/ES2725328T3/es active Active
- 2013-04-18 HU HUE13726297A patent/HUE043215T2/hu unknown
- 2013-04-18 EP EP13726297.8A patent/EP2841110B1/en active Active
- 2013-04-18 PT PT13726297T patent/PT2841110T/pt unknown
- 2013-04-18 JP JP2015507633A patent/JP6026645B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013160807A1 (en) | 2013-10-31 |
| HUE043215T2 (hu) | 2019-08-28 |
| CN104684586A (zh) | 2015-06-03 |
| PT2841110T (pt) | 2019-05-06 |
| EP2841110B1 (en) | 2019-01-09 |
| CN104684586B (zh) | 2019-02-05 |
| JP6026645B2 (ja) | 2016-11-16 |
| PL2841110T3 (pl) | 2019-08-30 |
| US9725491B2 (en) | 2017-08-08 |
| US20150141627A1 (en) | 2015-05-21 |
| JP2015515489A (ja) | 2015-05-28 |
| EP2841110A1 (en) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20210098473A (ko) | 조작된 세포외 소포체 및 이의 용도 | |
| JP6786074B2 (ja) | エキソソーム標的dnaワクチン | |
| WO2019170837A1 (en) | Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof | |
| JP2021506851A (ja) | 抗原−アジュバントカップリング試薬および使用の方法 | |
| ES2951684T3 (es) | Métodos y composiciones para estimular la respuesta inmune | |
| JP2025505603A (ja) | 細胞への標的化送達のための薬剤および方法 | |
| JP2023512562A (ja) | 人工シナプス | |
| WO2014198420A1 (en) | Low molecular weight immune-modulators as adjuvants for specific immunotherapy | |
| ES2718336T3 (es) | Liposomas que contienen fragmentos oligopeptídicos de proteína básica de mielina, una composición farmacéutica y un procedimiento de tratamiento de esclerosis múltiple | |
| Park et al. | Multilayer adjuvanted influenza protein nanoparticles improve intranasal delivery and antigen-specific immunity | |
| ES2291071B1 (es) | Agentes y metodos basados en el uso del dominio eda de la fibronectina. | |
| WO2019197563A2 (en) | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation | |
| US9539321B2 (en) | HMGB1-derived peptides enhance immune response to antigens | |
| US20260001938A1 (en) | Peptide used for immunotherapeutics | |
| Jackson et al. | Bioengineered small extracellular vesicles deliver multiple SARS‐CoV‐2 antigenic fragments and drive a broad immunological response | |
| US20240024438A1 (en) | Methods and compositions comprising mhc class peptides | |
| JP6026645B2 (ja) | 抗原送達方法 | |
| US20250295758A1 (en) | Novel peptide conjugate vaccines | |
| ES2833254T3 (es) | Presentación de anticuerpos biespecíficos sobre la superficie de fagos | |
| Langel | Toxicity and Immune Response | |
| Chaudhary | Engineering immunomodulatory nanoparticles for safe and potent RNA delivery | |
| WO2019216394A1 (ja) | ダニアレルギー治療のための核酸 | |
| Pho | Surface Engineering of Protein Nanoparticles for Intranasal Delivery | |
| TW202523699A (zh) | 靶向傳遞免疫效應子細胞之藥劑及方法 | |
| Senni | Role of the IRAP compartment in cross-presentation: deciphering molecular interactions and MHC-I trafficking |